Hib-DTaP vaccine - GlaxoSmithKline

Drug Profile

Hib-DTaP vaccine - GlaxoSmithKline

Alternative Names: Hib-DTP-acellular vaccine - GlaxoSmithKline; Infanrix-Hib

Latest Information Update: 22 Jan 2001

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Haemophilus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Marketed Diphtheria; Haemophilus infections; Pertussis; Tetanus

Most Recent Events

  • 22 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
  • 06 Apr 2000 Launched for Haemophilus infections in United Kingdom (IM)
  • 06 Apr 2000 Launched for Pertussis in United Kingdom (IM)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top